Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Immune Design in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.85.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Immune Design. This rating has held steady since January 2020, when it changed from a Hold consensus rating.
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.